Relationship between genetic polymorphism of cytochrome p450IIE1 and fatty liver

World Journal of Gastroenterology

Volumn 9, Issue 11, 2003, Pages 2612-2615

  Piao, Yun Feng ^a   Li, Jing Tao ^a   Shi, Yang ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2E1; RESTRICTION ENDONUCLEASE;

ALCOHOLISM; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DIABETES MELLITUS; DISEASE PREDISPOSITION; FATTY LIVER; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HETEROZYGOTE DETECTION; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MONONUCLEAR CELL; MORBIDITY; MUTANT; OBESITY; PATHOGENESIS; PERIPHERAL CIRCULATION; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; WILD TYPE;

EID: 0344036187     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i11.2612     Document Type: Article

References (38)

1. Koop DR. Oxidative and reductive metabolism by cytochrome P4502E1. FASEB J 1992; 6: 724-730
2. Gonzalez FJ, Gelboin HV. Transcriptional and posttranscriptional regulation of CYP 2E1, an N-nitrosodimethylamine demethylase. Princess Takamatsu Symp 1990; 21: 157-164
3. Ramaiah SK, Apte U, Mehendale HM. Cytochrome P450 2E1 induction increases thioacetamide liver injury in diet-restricted rats. Drug Metab Dispos 2001; 29: 1088-1095
4. Zangar RC, Benson JM, Burnett VL, Springer DL. Cytochrome P450 2E1 is the primary enzyme responsible for low-dose carbon tetrachloride metabolism in human liver microsomes. Chem Biol Interact 2000; 15: 233-243
5. Umeno M, McBride OW, Yang CS, Gelboin HV, Gonzalez FJ. Human ethanol-inducible P450IIE1: Complete gene sequence, promoter characterization, chromosome mapping, and cDNA-directed expression. Biochemistry 1988; 27: 9006-9013
6. Han XM, Zhou HH. Polymorphism of CYP450 and cancer susceptibility. Acta Pharmacol Sin 2000; 21: 673-679
7. Snawder JE, Lipscomb JC. Interindividual variance of cytochrome P450 forms in human hepatic microsomes: Correlation of individual forms with xenobiotic metabolism and implications in risk assessment. Regul Toxical Pharmacol 2000; 32: 200-209
8. Stephens EA, Taylor JA, Kaplan N, Yang CH, Hsieh LL, Lucier GW, Bell DA. Ethnic variation in the CYPE1 gene polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics 1994; 4: 185-192
9. Watanabe J, Hayashi S, Kawajiri K. Different regulation and expression of the human CYP2E1 gene due to the Ras I polymorphism in the 5′-flanking region. J Biochem 1994; 116: 321-326
10. Hu Y, Hakkola J, Oscarson M, Ingelman-Sundberg M. Structural and functional characterization of the 5′-flanking region of the rat and human cytochrome P4502E1 genes: Indentification of a polymorphic repeat in the human gene. Biochem Biophys Res Commun 1999; 263: 286-293
11. Hayashi SI, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of human cytochrome P450IIE1. J Biochem 1991; 110: 559-565
12. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002; 22: 185-194
13. Niemela O, Parkkila S, Juvonen RO, Viitala K, Gelboin HV, Pasanen M. Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver disease. J Hepatol 2000; 33: 893-901
14. Pirttiaho HI, Salmela PI, Sotaniemi EA, Pelkonen RO, Pitkanen U, Luoma PV. Drug metabolism in diabetic subjects with fatty livers. Br J Clin Pharmacol 1984; 18: 895-899
15. Karvonen I, Stengard JH, Huupponen R, Stenback FG, Sotaniemi EA. Effects of enzyme induction therapy on glucose and drug metabolism in obese mice model of non-insulin dependent diabetes mellitus. Diabetes Res 1989; 10: 85-92
16. Yang S, Zhu H, Li Y, Lin H, Gabrielson K, Trush MA, Diehl AM. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000; 378: 259-268
17. Vidali M, Stewart SF, Rolla R, Daly AK, Chen Y, Mottaran E, Jones DE, Leathart JB, Day CP, Albano E. Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease. Hepatology 2003; 37: 410-419
18. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001; 281: 1135-1139
19. Sinclair JF, Szakacs JG, Wood SG, Walton HS, Bement JL, Gonzalez FJ, Jeffery EH, Wrighton SA, Bement WJ, Sinclair PR. Short-term treatment with alcohols causes hepatic steatosis and enhances acetaminophen hepatotoxicity in Cyp2e1 (-/-) mice. Toxicol Appl Pharmacol 2000; 168: 114-122
20. Jarvelainen HA, Fang C, Ingelman-Sundberg M, Lukkari TA, Sippel H, Lindros KO. Kupffer cell inactivation alleviates ethanol-induced steatosis and CYP2E1 induction but not inflammatory responses in rat liver. J Hepatol 2000; 32: 900-910
21. Agundez J, Ladero J, Diaz-Rubio M, Benitez J. Rsa I polymorphism at the cytochrome P4502E1 locus is not related to the risk of alcohol-related severe liver disease. Liver 1996; 16: 380-383
22. Donohue TM Jr, Clemens DL, Galli A, Crabb D, Nieto N, Kato J, Barve SS. Use of cultured cells in assessing ethanol toxicity and ethanol-related metabolism. Alcohol Clin Exp Res 2001; 25: 87S-93S
23. Kunitoh S, Imaoka S, Hiroi T, Yabusaki Y, Monna T, Funae Y. Acetaldehyde as well as ethanol is metabolized by human CYPIIE1. J Pharmacol Exp Ther 1997; 280: 527-532
24. Ingelman-Sundberg M, Ronis MJ, Lindros KO, Eliasson E, Zhukov E. Ethanol-inducible cytochrome P4502E1: Regulation, enzymology and molecular biology. Alcohol Alcohol Supl 1994; 2: 131-139
25. Maher J. The CYP2E1 knockout delivers another punch: First ASH, now NASH. Alcoholic steatohepatitis. Nonalcoholic steatohepatitis. Hepatology 2001; 33: 311-312
26. Ekstrom G, Ingelman-Sundberg M. Rat liver nicrosomal NADPH-supported oxidase activity and peroxidation dependent on ethanol-inducible cytochrom P450. Biochem Pharmacol 1989; 38: 1313-1319
27. Albano E, Clot P, Morimoto M, Tomasi A, Ingelman-Sundberg M, French SW. Role of cytochrome-P4502E1-dependent formation of hydroxyethyl free radical in the development of liver damage in rats intragstrically fed with ethanol. Hepatology 1996; 23: 155-163
28. Clot P, Albano E, Eliasson E, Tabone M, Arico S, Israel Y, Moncada C, Ingelman-Sundberg M. Cytochrome P4502E1 hydroxyethyl radical adducts as the major antigen in autoantibody formation among alcoholics. Gastroenterology 1996; 111: 206-216
29. Albano E, French SW, Ingelmana-Sundberg M. Hydroxyethyl radical in ethanol hepatotoxicity. Front Biosci 1999; 4: 533-540
30. Britton RS, Bacon BR. Role of free radical in liver diseases and hepatic fibrosis. Hepatogastroenterology 1994; 41: 343-348
31. Iwahashi K, Miyatake R, Suwaki H, Kinoshita H, Ameno K, Ijii I, Ishikawa Y, Matsuo Y. Blood ethanol levels and CYPIIE1 allele. Arukoru Kenkyuto Yakubutsu Ison 1994; 29: 190-194
32. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-1075
33. Letteron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996; 24: 200-208
34. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P4502E1 is increased in patients with non-alcoholic steatohepatitis. Hepatology 1998; 27: 128-133
35. Weltman MD, Farrell GC, Liddle C. Increased CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111: 1645-1653
36. Raucy JL, Lasker JM, Kraner JC, Salazar DE, Lieber CS, Corcoran GB. Introduction of cytochrome P450IIE1 in the obese overfed rat. Mol Pharmacol 1991; 39: 275-280
37. Osmundsen H, Bremer J, Pedersen JI. Metabolic aspects of peroxisomal-oxidation. Biochim Biophys Acta 1991; 1085: 141-158
38. Zangar RC, Novak RF. Effects of fatty acids and ketone bodies on cytochromes P450 2B, 4A and 2E1 expression in primary cultured rat hepatocytes. Arch Biochem Biophys 1997; 337: 217-224